<DOC>
	<DOC>NCT01693159</DOC>
	<brief_summary>The SUPPORT trial is an open-label, prospective, randomized, national multicenter intervention study to evaluate the effectiveness of ethyl-2-cyanoacrylate versus the standard treatment of each institution on the pain intensity and QoL in patients with locally advanced head and neck cancer suffering from painful cetuximab-induced rhagades during radioimmunotherapy.</brief_summary>
	<brief_title>Effects of ECA on Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades</brief_title>
	<detailed_description />
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Ethyl 2-cyanoacrylate</mesh_term>
	<criteria>Locally advanced squamous cell carcinoma of the head and neck and participation in the HICAREphaseIVtrial Cetuximabinduced painful rhagades, i.e. SUPO Score 23 (see Figure 2) Compliance to the photo documentation Ability of subject to understand character and individual consequences of the clinical trial Written informed consent Cetuximabinduced rhagades without any pain, i.e. SUPO Score 1 Cetuximabinduced rhagades, SUPO Score 4, i.e. superinfection of the rhagades Patients not being enrolled in the HICARE trial Substance misuse, psychoactive substance abuse or psychological/social conditions leading to a decreased patients' compliance with possible bad influence to the results of the study Known allergic reaction to ethyl2cyanoacrylate (ECA)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Painful cetuximab-induced rhagades</keyword>
	<keyword>Radioimmunotherapy</keyword>
	<keyword>Head and neck cancer</keyword>
</DOC>